COMP <GO>
DGX vs MRK // FORWARD P/E MULTIPLE
Quest Diagnostics Incorporated (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: DGX 5
— MRK 10
▲ FORWARD P/E MULTIPLE LEADER: MRK
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
forward-pe
26.1x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 74.80% | -41.60 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | 20.70% | -10.40 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 15.3x | +1.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.88% | 3.42% | +1.46 | DGX | /fcf-yield <GO> |
| Operating Margin | 14.10% | 34.30% | -20.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 28.10% | -19.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 1.30% | +10.50 | DGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.27% | 2.26% | -0.99 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.01 | 5.19 | -1.18 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | DGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.3 | 56.9 | +11.47 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.92 | +0.09 | DGX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 26.1x | 18.4x | +7.70 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.83B | $361.02B | -$333.20B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | MRK REV | DGX GROSS % | MRK GROSS % | DGX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $65.01B | 33.2% | 74.8% | $1.36B | $12.36B |
| FY 2024 | $9.87B | $64.17B | 32.9% | 76.3% | $909.0M | $18.10B |
| FY 2023 | $9.25B | $60.12B | 44.0% | 44.0% | $855.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
MRK // BETA 0.92